Skip To Content

Study ID: TDN Celtaxsys CTX-4430-CF-201 EMPIRE Adult CF Study

Title:

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Patients with Cystic Fibrosis

Location:
Sioux Falls Region
Principal Investigator:
James Wallace, MD
Disease:
Lung
Stage:
Phase II
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.